A Phase 4 interventional study of Blood draw for insulin auto-anti body tests* in Type 1 Diabetes, sponsored by Sanofi. Completed at 1 site in Pakistan. Open to participants aged 2 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-25.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Diabetes Mellitus, Type 1 by Sanofi — 6 open to participants now, 10 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Sanofi.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 12th largest by enrollment of the 60 interventional ones that give a count, is one of 6 that started in 2017, is one of 14 in phase 4, and was the 46th registered.
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →6 of the 67 studies in Diabetes Mellitus, Type 1 by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Germany, Israel and 1 more country
Sanofi · Sites in Belgium, France, Germany and 3 more countries
Sanofi · Sites in Kuwait, Saudi Arabia, United Arab Emirates
Ages 18 mo–18 yrs · Healthy volunteers
Sanofi · Sites in United States
Ages 8+
Sanofi · Sites in United States, Argentina, Australia and 17 more countries
Ages 1–25
By country, each count listing its studies:
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 2 Years to 20 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 6 · Phase 3 20 · Phase 4 14
First in 2001; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 375 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 86 across the 60 interventional studies, 194 across the 6 observational. Of the 56 that completed or were terminated, 13 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
5 of the studies in Diabetes Mellitus, Type 1 by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04598893Provention Bio, a Sanofi CompanyRecent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension) | 2026-11 |
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT06111586SanofiFrexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS) | 2027-04-28 |
| NCT06812988SanofiTreatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule | 2027-04-29 |
| NCT07038473SanofiEarly Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF) | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To measure the association between a parental history of diabetes and the odds of an offspring being Type 1 diabetics.
Secondary Objectives:
The overall duration of this study is expected to be 12 months. The recruitment period for a given center will be four months following site initiation of that center. telephonic follow-up for all the patients shall be conducted after 15 days ± 5 days.
*Each patient (cases as well as controls) will be required to undergo laboratory tests for insulin autoantibodies and hemoglobin A1c tests. Both the tests will be conducted through centralized laboratories for all recruited patients.
Since the result of insulin auto-antibodies test is one of the inclusion criteria, it is mandatory for all patients to undergo this test, and detailed information for the same has been included in the informed consent form.
Inclusion criteria :
Inclusion Criteria for Cases
Inclusion Criteria for Controls
Exclusion criteria:
Exclusion Criteria for Cases:
Exclusion Criteria for Controls:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Known cases of type 1 diabetes mellitus as described in the inclusion criteria for cases
Drug: Blood draw for insulin auto-anti body tests*
Age-matched non-diabetic controls as described in the inclusion criteria for controls
Drug: Blood draw for insulin auto-anti body tests*
Pharmaceutical form: N/A Route of administration: N/A
Odds of Type 1 Diabetes Mellitus child having a diabetic parent
Odds ratio will be used to calculate and measure disease frequency from dichotomous categorical variables
Time frame: 12 months
Characterization of this population by gender
Categorical variables (gender) will be presented as proportions
Time frame: 12 months
Characterization of this population by age
Categorical variables (age) will be presented as proportions
Time frame: 12 months
Characterization of this population by socio-economic profile
Categorical variables (socio-economic profile) will be presented as proportions
Time frame: 12 months
Means of HbA1c in Type 1 diabetes mellitus (T1DM) patients
Mean HbA1c
Time frame: 12 months
Standard deviation of HbA1c in T1DM patients
Standard deviation of HbA1c
Time frame: 12 months
Distribution of prescribed therapies by type of insulin to T1DM patients
Distribution of prescribed therapies by type of insulin will be presented as proportions
Time frame: 12 months
Means of fasting blood glucose (FBG) in T1DM patients
Mean Fasting Blood Glucose
Time frame: 12 months
Standard deviation of FBG in T1DM patients
Standard deviation of FBG
Time frame: 12 months
Duration of diabetes in parent
Mean duration of diabetes in parent
Time frame: 12 months
Mean duration of diabetes in parent
Standard deviation of duration of diabetes in parent
Time frame: 12 months
Characterization of family history of diabetes
Categorical variables will be measured as proportions
Time frame: 12 months
Characterization of frequency of consultation
Number of consultations per month
Time frame: 12 months
Characterization of diabetes education
Number of sessions per month
Time frame: 12 months
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Ran from Oct 2017 to primary completion in Aug 2018, 10 months.
Of 74 phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.